KR100932071B1 - Method for preparing benzal acetophenone derivative - Google Patents

Method for preparing benzal acetophenone derivative Download PDF

Info

Publication number
KR100932071B1
KR100932071B1 KR1020070094617A KR20070094617A KR100932071B1 KR 100932071 B1 KR100932071 B1 KR 100932071B1 KR 1020070094617 A KR1020070094617 A KR 1020070094617A KR 20070094617 A KR20070094617 A KR 20070094617A KR 100932071 B1 KR100932071 B1 KR 100932071B1
Authority
KR
South Korea
Prior art keywords
methoxyphenyl
hydroxy
prop
formula
compound
Prior art date
Application number
KR1020070094617A
Other languages
Korean (ko)
Other versions
KR20090029410A (en
Inventor
오세관
정재철
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Priority to KR1020070094617A priority Critical patent/KR100932071B1/en
Publication of KR20090029410A publication Critical patent/KR20090029410A/en
Application granted granted Critical
Publication of KR100932071B1 publication Critical patent/KR100932071B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/784—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/788—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with keto groups bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/792—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic containing rings other than six-membered aromatic rings

Abstract

본 발명은 하기 화학식 1의 벤잘아세토페논 (benzalacetophenone) 유도체의 제조방법에 관한 것으로, 본 발명에 따른 방법을 이용하면 한단계 반응 (One pot)으로 고순도의 벤잘아세토페논 유도체를 제조할 수 있을 뿐만 아니라 경제적으로 제조효율을 높일 수 있어 산업적으로 유용하다.The present invention relates to a method for preparing a benzalacetophenone derivative of Formula 1 below, by using the method according to the present invention it is possible to prepare a high purity benzalacetophenone derivative in one pot reaction as well as economic It is possible to increase the manufacturing efficiency, which is useful industrially.

<화학식 1><Formula 1>

Figure 112007067440798-pat00001
Figure 112007067440798-pat00001

상기 식에서, Where

R1 내지 R6, X 및 Y는 명세서 내에 정의한 바와 같다. R 1 To R 6 , X and Y are as defined in the specification.

Description

벤잘아세토페논 유도체의 제조방법{METHOD FOR THE PREPARATION OF BENZALACETOPHENONE DERIVATIVES}Method for producing benzal acetophenone derivatives {METHOD FOR THE PREPARATION OF BENZALACETOPHENONE DERIVATIVES}

본 발명은 벤잘아세토페논 유도체를 효과적으로 제조하는 방법에 관한 것이다. The present invention relates to a method for effectively preparing benzalacetophenone derivatives.

벤잘아세토페논 (benzalacetophenone) 유도체는 의약, 농약 및 화장품 분야에서 광범위하게 적용되고 있는 활성성분으로서, 항염증효과, 항암효과, 항생효과 및 항바이러스효과 등이 있는 것으로 알려져있다. 최근에 이들 화합물은 항산화효과, 선충구제효과, 지질과산화 저해효과 및 아실 CoA 저해효과를 나타낼 뿐만 아니라 허혈증, 파킨슨병, 알츠하이머병, 및 헌팅톤병과 같은 정신질환에 탁월한 효과가 있는 것으로 밝혀졌다.Benzalacetophenone derivatives are widely used in medicine, pesticides and cosmetics, and are known to have anti-inflammatory, anti-cancer, antibiotic and antiviral effects. Recently, these compounds have been shown to exhibit antioxidant effects, nematode control effects, lipid peroxidation inhibitory effects and acyl CoA inhibitory effects, as well as excellent effects on mental diseases such as ischemia, Parkinson's disease, Alzheimer's disease, and Huntington's disease.

본 발명이 목적하는 하기 화학식 1로 표시되는 화합물은 플라보노이드, 페놀류의 유도체 및 벤질리덴 아세토페논 유도체의 주요 중간체로 사용될 뿐만 아니라 농약의 중간체로도 매우 유용한 것으로 알려져 있고, 이의 제조방법에 대해서도 여 러 문헌에 공지되어 있다 (문헌 [Lawrence, N. J., et al., Bioorg. & Med. Chem. Lett., 16:5844-5848, 2006]; [Kim, D. Y., et al., J. Med . Chem., 49:5664-5670, 2006]; 및 [Satyanarayana, M., et al., Bioorg . & Med . Chem., 12:883-889, 2004] 참조). The compound represented by the following general formula (1), which is the object of the present invention, is not only used as a main intermediate of flavonoids, phenol derivatives and benzylidene acetophenone derivatives, but also is very useful as an intermediate of pesticides. (Lawrence, NJ, et al., Bioorg. & Med. Chem. Lett ., 16: 5844-5848, 2006); Kim, DY, et al., J. Med . Chem ., 49: 5664-5670, 2006; and Satyanarayana, M., et al., Bioorg . & Med . Chem ., 12: 883-889, 2004).

Figure 112007067440798-pat00002
Figure 112007067440798-pat00002

상기 식에서, Where

X는 CH, CF, CCl, CI 또는 N이고;X is CH, CF, CCl, CI or N;

Y는 C 또는 N이고; Y is C or N;

R1은 수소, 하이드록시, C1-C6알킬, C1-C6알콕시, 실릴 또는 벤질이고;R 1 is hydrogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, silyl or benzyl;

R2 및 R3는 각각 독립적으로 수소, 하이드록시, C1-C6알킬, C1-C6알킬실릴이고;R 2 And R 3 are each independently hydrogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkylsilyl;

R4, R5 및 R6는 각각 독립적으로 수소, C1-C6알킬, 아실, 할로겐 원자, C1-C6할로알킬, C1-C6알콕시, 아미노, 나이트로 또는 산소 원자이거나, 함께 연결되어 고리화합물을 형성한다.R 4 , R 5 and R 6 are each independently hydrogen, C 1 -C 6 alkyl, acyl, halogen atom, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, amino, nitro or oxygen atom, or are linked together To form cyclic compounds.

그 중, 대표적인 제조방법은 하기 반응식 1에 나타낸 바와 같이, 화학식 4의 신남알데하이드 화합물과 화학식 5의 그리냐드 화합물을 상온에서 반응시켜 화학식 6의 알코올 화합물을 제조하고, 이를 용매 존재 하에서 산화제로 산화시키는 여러 단계의 반응을 거쳐 목적 화합물인 하기 화학식 7의 벤잘아세토페논 유도체를 제조하는 방법이다 (문헌 [Lee, H. J., et al., Chem . Pharm . Bull., 54:377-379, 2006]; [Weber, W. M., et al., Bioorg . & Med . Chem., 13:3811-3820, 2005]; 및 [Oh, S., et al., Arch . Pharm . Res., 29:469-475, 2006] 참조).Among them, as shown in Scheme 1 below, a cinnamic aldehyde compound of Formula 4 and a Grignard compound of Formula 5 are reacted at room temperature to prepare an alcohol compound of Formula 6, which is oxidized with an oxidizing agent in the presence of a solvent. It is a method for preparing a benzalacetophenone derivative of the general formula (7) which is a target compound through several steps of reaction (Lee, HJ, et al., Chem . Pharm . Bull ., 54: 377-379, 2006); [ Weber, WM, et al., Bioorg . & Med . Chem ., 13: 3811-3820, 2005; and Oh, S., et al., Arch . Pharm . Res ., 29: 469-475, 2006 ] Reference).

Figure 112007067440798-pat00003
Figure 112007067440798-pat00003

상기 식에서, R1 내지 R6, X 및 Y는 상기 화학식 1에서 정의한 바와 같다. Wherein, R 1 to R 6 , X and Y are as defined in Formula 1 above.

그러나, 상기 반응식 1에 따른 벤잘아세토페논 유도체의 제조방법은 그리냐드 시약 및 산화제를 사용하는 등 반응조건이 격렬하고, 전체 제조공정이 복잡하고 길어 수율이 저조할 뿐만 아니라, 화학시약이 유리되어 환경에 부담이 되는 등의 문제점이 있다.However, the method for preparing benzalacetophenone derivatives according to Scheme 1 is such that using Grignard reagent and an oxidizing agent, the reaction conditions are violent, the overall manufacturing process is complicated and long, and the yield is low, and the chemical reagent is free. There is a problem such as a burden.

따라서, 보다 온화한 반응조건을 유지하면서 제조공정이 간단하고, 고순도 및 고수율로 벤잘아세토페논 유도체를 제조할 수 있는 개선된 제조방법의 개발이 요구되어 왔다.Therefore, there has been a need for the development of an improved production method which is simple in the production process while maintaining milder reaction conditions, and can produce benzalacetophenone derivatives in high purity and high yield.

따라서, 본 발명의 목적은 종래에 알려진 벤잘아세토페논 유도체의 제조방법에 있어서 보다 간단하면서도 고순도 및 고수율로 벤잘아세토페논 유도체를 제조하는 방법을 제공하는 것이다. Accordingly, it is an object of the present invention to provide a method for producing benzalacetophenone derivatives in a simpler, higher purity and higher yield in the conventionally known method for producing benzalacetophenone derivatives.

상기 목적을 달성하기 위하여 본 발명은, 하기 화학식 2의 화합물과 화학식 3의 화합물을 용매 존재 하에서 염기와 반응시켜 하기 화학식 1의 벤잘아세토페논 유도체를 제조하는 방법을 제공한다: In order to achieve the above object, the present invention provides a method for preparing a benzalacetophenone derivative of formula 1 by reacting a compound of formula 2 and a compound of formula 3 with a base in the presence of a solvent:

<화학식 1><Formula 1>

Figure 112007067440798-pat00004
Figure 112007067440798-pat00004

Figure 112007067440798-pat00005
Figure 112007067440798-pat00005

Figure 112007067440798-pat00006
Figure 112007067440798-pat00006

상기 식에서, Where

X는 CH, CF, CCl, CI 또는 N이고;X is CH, CF, CCl, CI or N;

Y는 C 또는 N이고; Y is C or N;

R1은 수소, 하이드록시, C1-C6알킬, C1-C6알콕시, 실릴 또는 벤질이고;R 1 is hydrogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, silyl or benzyl;

R2 및 R3는 각각 독립적으로 수소, 하이드록시, C1-C6알킬, C1-C6알킬실릴이고;R 2 And R 3 are each independently hydrogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkylsilyl;

R4, R5 및 R6는 각각 독립적으로 수소, C1-C6알킬, 아실, 할로겐 원자, C1-C6할로알킬, C1-C6알콕시, 아미노, 나이트로 또는 산소 원자이거나, 함께 연결되어 고리화합물을 형성한다.R 4 , R 5 and R 6 are each independently hydrogen, C 1 -C 6 alkyl, acyl, halogen atom, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, amino, nitro or oxygen atom, or are linked together To form cyclic compounds.

본 발명에 따른 제조방법에 따르면, 의약 및 농약 그리고 화장품분야에서 광범위하게 적용되고 있는 벤잘아세토페논 유도체를 온화한 반응조건을 유지하면서 한단계 반응으로 간단하게 고순도 및 고수율로 제조할 수 있으므로, 본 발명의 방법은 상기 유도체의 공업적 제조에 유용하다.According to the production method according to the present invention, benzalacetophenone derivatives widely applied in the fields of medicine, agrochemicals and cosmetics can be easily produced in high purity and high yield in one step reaction while maintaining mild reaction conditions. The method is useful for the industrial preparation of such derivatives.

본 발명에 따른 제조방법을 개략적으로 설명하면 하기 반응식 2에 도시한 바와 같다.The manufacturing method according to the present invention is briefly described as shown in Scheme 2 below.

Figure 112007067440798-pat00007
Figure 112007067440798-pat00007

상기 식에서, R1 내지 R6, X 및 Y는 상기에서 정의한 바와 같고, R4, R5 및 R6가 서로 연결되어 형성할 수 있는 고리화합물로는 1,3-다이옥솔, 1,4-다이옥신, 벤조이미다졸 또는 퀴녹사졸린 화합물을 들 수 있다.Wherein R 1 to R 6 , X and Y are as defined above, R 4 , Examples of the cyclic compound in which R 5 and R 6 may be linked to each other include 1,3-dioxol, 1,4-dioxin, benzoimidazole, or quinoxazoline compound.

본 발명의 제조방법은 일당량의 상기 화학식 2의 알데하이드 화합물, 일당량 의 상기 화학식 3의 아세토페논 화합물 및 일당량의 염기를 알코올 용매 하에서 반응시켜 한단계 반응 (One pot)으로 간단하게 상기 화학식 1의 벤잘아세토페논 유도체를 제조하는 것을 특징으로 한다. In the preparation method of the present invention, one equivalent of the aldehyde compound of Chemical Formula 2, one equivalent of the acetophenone compound of Chemical Formula 3, and one equivalent of the base is reacted in an alcohol solvent to simplify the reaction of Chemical Formula 1 in one pot. It is characterized by preparing a benzalacetophenone derivative.

본 발명에서 출발물질로 사용되는 상기 화학식 2의 화합물로는 바닐린 (vanillin, 4-hydroxy-3-methoxybenzaldehyde), 아이소바닐린 (isovanillin, 3-hydroxy-4-methoxybenzaldehyde), 오쏘 바닐린 (O-vanillin, 2-hydroxy-3-methoxybenzaldehyde) 또는 3,4-다이메톡시벤즈알데하이드가 사용될 수 있고, 상기 화학식 3의 화합물로는 아세토페논, 트라이메틸실릴아세토페논, 3,4-메틸렌다이옥시아세토페논, 4-트라이플루오로메틸아세토페논, 3,4,5-트라이플루오로아세토페논 또는 3-플루오로-4-메톡시아세토페논이 사용될 수 있다. Compounds of the formula (2) used as starting materials in the present invention is vanillin (vanillin, 4-hydroxy-3-methoxybenzaldehyde), isovanillin (isovanillin, 3-hydroxy-4-methoxybenzaldehyde), ortho vanillin (O-vanillin, 2 -hydroxy-3-methoxybenzaldehyde) or 3,4-dimethoxybenzaldehyde, and the compound of Formula 3 may be acetophenone, trimethylsilylacetophenone, 3,4-methylenedioxyacetophenone, 4- Trifluoromethylacetophenone, 3,4,5-trifluoroacetophenone or 3-fluoro-4-methoxyacetophenone can be used.

상기 화학식 2의 화합물과 상기 화학식 3의 화합물은 1:1의 당량비로 반응시키는 것이 바람직하며, 이때 사용할 수 있는 유기용매로는 다이클로로메탄, 클로로포름, 아세토나이트릴, 다이메틸폼알데하이드, 다이메틸설폭사이드 및 이들의 혼합물, 또는 메탄올, 에탄올, 부탄올, 물 및 이들의 혼합물을 사용할 수 있으며, 메탄올을 사용하는 것이 바람직하다. 또한, 상기 반응은 0 내지 50℃에서 1 내지 200 시간 동안 수행되는 것이 바람직하다.The compound of Formula 2 and the compound of Formula 3 are preferably reacted in an equivalent ratio of 1: 1. In this case, as an organic solvent that can be used, dichloromethane, chloroform, acetonitrile, dimethylformaldehyde, and dimethyl sulfoxide And mixtures thereof, or methanol, ethanol, butanol, water and mixtures thereof, and it is preferable to use methanol. In addition, the reaction is preferably carried out at 0 to 50 ℃ for 1 to 200 hours.

또한, 본 발명에서 사용될 수 있는 염기로는 통상적으로 널리 사용되는 리튬하이드록사이드 (LiOH), 소듐하이드록사이드 (NaOH), 포타슘하이드록사이드 (KOH), 마그네슘하이드록사이드 (Mg(OH)2) 및 바륨하이드록사이드 (Ba(OH)2) 등을 들 수 있 으나, 리튬하이드록사이드 (LiOH)를 사용하는 것이 바람직하다.In addition, as the base that can be used in the present invention, lithium hydroxide (LiOH), sodium hydroxide (NaOH), potassium hydroxide (KOH), magnesium hydroxide (Mg (OH) 2 ), which are commonly used widely, ) And barium hydroxide (Ba (OH) 2 ), but lithium hydroxide (LiOH) is preferred.

상기 반응이 완결되면 반응 혼합액으로부터 화학식 1의 벤잘아세토페논 유도체를 당분야에서 널리 알려진 통상의 방법, 예를 들면 컬럼 크로마토그래피법, 고체석출법, 재결정법 등을 사용하여 회수할 수 있으며, 이 중 컬럼 크로마토그래피법이 가장 일반적이고 회수율이 높지만 고체석출법 또는 재결정법이 경제적으로 유용한 회수방법이라 할 수 있다.Upon completion of the reaction, the benzalacetophenone derivative of formula 1 may be recovered from the reaction mixture using conventional methods well known in the art, such as column chromatography, solid precipitation, recrystallization, and the like. Column chromatography is the most common and high recovery, but solid precipitation or recrystallization is economically useful recovery method.

본 발명에 따라 제조된 벤잘아세토페논 유도체 화합물은 상기 화학식 1에서 X 및 Y가 CH이고; R1이 수소, 하이드록시 또는 C1-C6알콕시이고; R2 및 R3가 각각 독립적으로 수소 또는 C1-C6알킬이고; R4 및 R5가 각각 독립적으로 수소, C1-C6알킬, 할로겐 원자, C1-C6할로알킬, C1-C6알콕시 또는 산소 원자이거나, 함께 연결되어 고리화합물을 형성하고; R6가 수소 또는 할로겐 원자인 화합물이 바람직하고, 상기 고리화합물은 1,3-다이옥솔 또는 1,4-다이옥신이 바람직하다. In the benzalacetophenone derivative compound prepared according to the present invention, in Formula 1, X and Y are CH; R 1 is hydrogen, hydroxy or C 1 -C 6 alkoxy; R 2 And R 3 are each independently hydrogen or C 1 -C 6 alkyl; R 4 and Each R 5 is independently hydrogen, C 1 -C 6 alkyl, halogen atom, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or oxygen atom, or are linked together to form a cyclic compound; A compound in which R 6 is hydrogen or a halogen atom is preferable, and the cyclic compound is preferably 1,3-dioxol or 1,4-dioxin.

또한, 본 발명의 화학식 1에 속하는 대표적인 화합물을 하기 표 1과 같이 나타낼 수 있다. In addition, the representative compounds belonging to the general formula (1) of the present invention can be represented as shown in Table 1.

Figure 112007067440798-pat00008
Figure 112007067440798-pat00008

Figure 112007067440798-pat00009
Figure 112007067440798-pat00009

이와 같이, 화학식 2의 화합물, 화학식 3의 화합물 및 염기를 알코올 용매 하에서 한단계 반응으로 반응시켜 화학식 1의 벤잘아세토페논 화합물을 제조하는 본 발명의 방법에 의하면, 종래의 방법보다 온화한 반응조건으로도 고순도 및 고수율로 목적 화합물을 제조할 수 있다.As described above, according to the method of the present invention for preparing the benzalacetophenone compound of Formula 1 by reacting the compound of Formula 2, the compound of Formula 3, and the base in an alcoholic reaction, it is possible to obtain a high purity even under milder conditions than conventional methods. And the desired compound in high yield.

이하, 본 발명을 하기 실시예에 의거하여 좀더 상세하게 설명하고자 한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐 한정하지는 않는다.Hereinafter, the present invention will be described in more detail based on the following examples. However, the following examples are not intended to limit the invention only.

실시예 1Example 1 : (: ( EE )-3-(4-하이드록시-3-메톡시페닐)-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (4-hydroxy-3-methoxyphenyl) -1-phenylprop-2-en-1-one

아세토페논 (6.0 mmol)을 메탄올 (30 ㎖)에 용해시킨 후, LiOH (1.2 mmol)를 첨가하여 1시간 동안 상온에서 교반한 다음, 반응액에 바닐린 (6.0 mmol)을 첨가하고 상온에서 약 96시간 동안 교반하였다. 반응 혼합물의 용매를 감압 하에 제거한 후, 물 (35 ㎖)을 가하고 10% 염산으로 중화한 다음, 다이클로로메탄 (40 ㎖)으로 추출하여 유기층을 분리하고, 무수 황산마그네슘으로 건조하여 여과하였다. 상기 여액의 용매를 감압 하에 제거한 후, 잔사를 컬럼 크로마토그래피로 분리정제하여 표제 화합물 (수율: 90%)을 얻었다.Acetophenone (6.0 mmol) was dissolved in methanol (30 mL), followed by addition of LiOH (1.2 mmol) and stirring at room temperature for 1 hour, followed by addition of vanillin (6.0 mmol) to the reaction solution at room temperature for about 96 hours. Was stirred. After the solvent of the reaction mixture was removed under reduced pressure, water (35 mL) was added, neutralized with 10% hydrochloric acid, extracted with dichloromethane (40 mL), the organic layer was separated, dried over anhydrous magnesium sulfate, and filtered. After removing the solvent of the filtrate under reduced pressure, the residue was purified by column chromatography to give the title compound (yield: 90%).

R f = 0.4 (20% 에틸아세테이트/헥산); R f = 0.4 (20% ethyl acetate / hexanes);

IR (neat, NaCl) 3321, 3070, 3001, 2960, 1739, 1656, 1420, 1285, 1038 cm-1;IR (neat, NaCl) 3321, 3070, 3001, 2960, 1739, 1656, 1420, 1285, 1038 cm −1 ;

1H NMR (400 MHz, CDCl3) δ 8.02 (d, J=5.4 Hz, 2H), 7.76 (d, J=11.7 Hz, 1H), 7.58 (t, J=5.1 Hz, 1H), 7.50 (d, J=5.4 Hz, 2H), 7.38 (d, J=11.7 Hz, 1H), 7.21 (d, J=6.0 Hz, 1H), 7.14 (s, 1H), 6.96 (d, J=6.0 Hz, 1H), 5.66 (brs, 1H), 3.95 (s, 3H, OMe); 1 H NMR (400 MHz, CDCl 3 ) δ 8.02 (d, J = 5.4 Hz, 2H), 7.76 (d, J = 11.7 Hz, 1H), 7.58 (t, J = 5.1 Hz, 1H), 7.50 (d , J = 5.4 Hz, 2H), 7.38 (d, J = 11.7 Hz, 1H), 7.21 (d, J = 6.0 Hz, 1H), 7.14 (s, 1H), 6.96 (d, J = 6.0 Hz, 1H ), 5.66 (brs, 1 H), 3.95 (s, 3 H, OMe);

13C NMR (100 MHz, CDCl3) δ 191.1, 149.0, 147.4, 145.7, 138.9, 132.9, 128.9, 128.8, 127.8, 123.8, 120.1, 115.4, 110.6, 56.4; 13 C NMR (100 MHz, CDCl 3 ) δ 191.1, 149.0, 147.4, 145.7, 138.9, 132.9, 128.9, 128.8, 127.8, 123.8, 120.1, 115.4, 110.6, 56.4;

HRMS: C16H15O3에 대한 이론치 255.1051 [M+H]+, 실측치 255.1038.HRMS: calc. For C 16 H 15 O 3 255.1051 [M + H] + , found 255.1038.

실시예 2Example 2 : : (E(E )-3-(4-하이드록시-3-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (4-hydroxy-3-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one

아세토페논 대신 3,4-메틸렌다이옥시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 75%)을 얻었다. The title compound (yield: 75%) was obtained in the same manner as in Example 1, except that 3,4-methylenedioxyacetophenone was used instead of acetophenone.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3349, 3007, 2955, 2876, 1645, 1554, 1477, 1243, 1186, 1045 cm-1; IR (neat, NaCl) 3349, 3007, 2955, 2876, 1645, 1554, 1477, 1243, 1186, 1045 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.11-6.72 (m, 6H), 6.59 (dd, J=7.5, 7.0 Hz, 1H), 6.38 (dd, J=7.0, 7.0 Hz, 1H), 6.05 (s, 2H), 3.88 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.11-6.72 (m, 6H), 6.59 (dd, J = 7.5, 7.0 Hz, 1H), 6.38 (dd, J = 7.0, 7.0 Hz, 1H), 6.05 ( s, 2H), 3.88 (s, 3H, OMe);

13C NMR (125 MHz, CDCl3) δ 188.9, 151.1, 147.0, 146.3, 145.7, 138.3, 133.5, 127.9, 126.5, 125.4, 122.1, 121.4, 120.5, 112.1, 102.5, 55.9; 13 C NMR (125 MHz, CDCl 3 ) δ 188.9, 151.1, 147.0, 146.3, 145.7, 138.3, 133.5, 127.9, 126.5, 125.4, 122.1, 121.4, 120.5, 112.1, 102.5, 55.9;

HRMS: C17H15O5에 대한 이론치 299.0919 [M+H]+, 실측치 299.0928.HRMS: calcd for C 17 H 15 O 5 299.0919 [M + H] + , found 299.0928.

실시예 3Example 3 : (: ( EE )-3-(4-하이드록시-3-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (4-hydroxy-3-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one

아세토페논 대신 4-트라이플루오로메틸아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 71%)을 얻었다. The title compound (yield: 71%) was obtained in the same manner as in Example 1, except that 4-trifluoromethylacetophenone was used instead of acetophenone.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3384, 3011, 2964, 2876, 1658, 1585, 1512, 1452, 1323, 1272, 1125, 1033 cm-1; IR (neat, NaCl) 3384, 3011, 2964, 2876, 1658, 1585, 1512, 1452, 1323, 1272, 1125, 1033 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 8.09 (d, J=8.0 Hz, 2H), 7.76 (dd, J=6.5, 6.5 Hz, 3H), 7.34 (d, J=16.0, Hz, 1H), 7.23 (dd, J=1.5, 1.5 Hz, 1H), 7.15 (d, J=1.5 Hz, 1H), 6.97 (d, J=8.0 Hz, 1H), 3.96 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 8.09 (d, J = 8.0 Hz, 2H), 7.76 (dd, J = 6.5, 6.5 Hz, 3H), 7.34 (d, J = 16.0, Hz, 1H), 7.23 (dd, J = 1.5, 1.5 Hz, 1H), 7.15 (d, J = 1.5 Hz, 1H), 6.97 (d, J = 8.0 Hz, 1H), 3.96 (s, 3H, OMe);

13C NMR (125 MHz, CDCl3) δ 189.6, 149.4, 146.1, 145.9, 145.0, 138.5, 133.2, 128.3, 126.8, 124.1, 120.0, 115.6, 111.4, 56.1; 13 C NMR (125 MHz, CDCl 3 ) δ 189.6, 149.4, 146.1, 145.9, 145.0, 138.5, 133.2, 128.3, 126.8, 124.1, 120.0, 115.6, 111.4, 56.1;

HRMS: C17H13F3O3에 대한 이론치 345.0714 [M+Na]+, 실측치 345.0725.HRMS: calcd for C 17 H 13 F 3 O 3 345.0714 [M + Na] + , found 345.0725.

실시예 4Example 4 : : (E(E )-3-(4-하이드록시-3-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (4-hydroxy-3-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one

아세토페논 대신 3,4,5-트라이플루오로아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 78%)을 얻었다.The title compound (yield: 78%) was obtained in the same manner as in Example 1, except that 3,4,5-trifluoroacetophenone was used instead of acetophenone.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3350, 3005, 2985, 2858, 1657, 1550, 1448, 1262, 1153, 1081 cm-1; IR (neat, NaCl) 3350, 3005, 2985, 2858, 1657, 1550, 1448, 1262, 1153, 1081 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.83 (d, J=16.0 Hz, 1H), 7.66 (t, J=8.0 Hz, 2H), 7.22 (d, J=16.0 Hz, 1H), 7.20 (d, J=8.5 Hz, 1H), 7.15 (s, 1H), 6.93 (d, J=8.0 Hz, 1H), 3.90 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.83 (d, J = 16.0 Hz, 1H), 7.66 (t, J = 8.0 Hz, 2H), 7.22 (d, J = 16.0 Hz, 1H), 7.20 (d , J = 8.5 Hz, 1H), 7.15 (s, 1H), 6.93 (d, J = 8.0 Hz, 1H), 3.90 (s, 3H, OMe);

13C NMR (125 MHz, CDCl3) δ 187.3, 151.0, 148.2, 146.5, 132.2, 128.3, 122.9, 121.7, 119.3, 113.1, 112.2, 111.9, 55.8; 13 C NMR (125 MHz, CDCl 3 ) δ 187.3, 151.0, 148.2, 146.5, 132.2, 128.3, 122.9, 121.7, 119.3, 113.1, 112.2, 111.9, 55.8;

HRMS: C16H12F3O3에 대한 이론치 309.0739 [M+H]+, 실측치 309.0745.HRMS: calcd for C 16 H 12 F 3 O 3 309.0739 [M + H] + , found 309.0745.

실시예 5Example 5 : (: ( EE )-1-(3-플루오로-4-메톡시페닐)-3-(4-하이드록시-3-메톡시페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -1- (3-fluoro-4-methoxyphenyl) -3- (4-hydroxy-3-methoxyphenyl) -1-prop-2-en-1-one

아세토페논 대신 3-플루오로-4-메톡시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 82%)을 얻었다. The title compound (yield: 82%) was obtained in the same manner as in Example 1, except that 3-fluoro-4-methoxyacetophenone was used instead of acetophenone.

R f = 0.3 (40% 에틸아세테이트/헥산); R f = 0.3 (40% ethyl acetate / hexanes);

IR (neat, NaCl) 3359, 2987, 2875, 1662, 1578, 1455, 1278, 1164, 1086 cm-1; IR (neat, NaCl) 3359, 2987, 2875, 1662, 1578, 1455, 1278, 1164, 1086 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.85-7.72 (m, 3H), 7.33 (d, J=16.0 Hz, 1H), 7.15 (d, J=8.5 Hz, 1H), 7.13 (s, 1H), 7.04 (t, J=8.5 Hz, 1H), 6.91 (d, J=8.0 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.85-7.72 (m, 3H), 7.33 (d, J = 16.0 Hz, 1H), 7.15 (d, J = 8.5 Hz, 1H), 7.13 (s, 1H) , 7.04 (t, J = 8.5 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 3H, OMe);

13C NMR (125 MHz, CDCl3) δ 189.4, 150.3, 148.7, 145.2, 132.4, 129.6, 124.9, 123.1, 121.8, 119.5, 115.3, 113.2, 111.8, 56.8, 55.9; 13 C NMR (125 MHz, CDCl 3 ) δ 189.4, 150.3, 148.7, 145.2, 132.4, 129.6, 124.9, 123.1, 121.8, 119.5, 115.3, 113.2, 111.8, 56.8, 55.9;

HRMS: C17H16FO4에 대한 이론치 303.1033 [M+H]+, 실측치 303.1020.HRMS: calc. For C 17 H 16 FO 4 303.1033 [M + H] + , found 303.1020.

실시예 6Example 6 : (: ( EE )-3-(3-하이드록시-4-메톡시페닐)-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (3-hydroxy-4-methoxyphenyl) -1-phenylprop-2-en-1-one

바닐린 대신 아이소바닐린을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 87%)을 얻었다. The title compound (yield: 87%) was obtained in the same manner as in Example 1, except that isoaniline was used instead of vanillin.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3348, 2983, 1684, 1545, 1468, 1280, 1144, 1081 cm-1; IR (neat, NaCl) 3348, 2983, 1684, 1545, 1468, 1280, 1144, 1081 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 8.01 (d, J=8.2 Hz, 2H, Ar H), 7.75 (d, J=15.6 Hz, 1H, vinyl), 7.68-7.18 (m, 5H, Ar H), 7.12 (d, J=8.3 Hz, 1H, Ar H), 6.87 (d, J=8.3 Hz, 1H, vinyl), 5.77 (s, 1H, OH), 3.94 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 8.01 (d, J = 8.2 Hz, 2H, Ar H), 7.75 (d, J = 15.6 Hz, 1H, vinyl), 7.68-7.18 (m, 5H, Ar H ), 7.12 (d, J = 8.3 Hz, 1H, Ar H), 6.87 (d, J = 8.3 Hz, 1H, vinyl), 5.77 (s, 1H, OH), 3.94 (s, 3H, OMe);

HRMS: C16H15O4에 대한 이론치 255.1021 [M+H]+, 실측치 255.1035.HRMS: calc. For C 16 H 15 O 4 255.1021 [M + H] + , found 255.1035.

실시예 7Example 7 : (: ( EE )-3-(3-하이드록시-4-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (3-hydroxy-4-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one

바닐린 대신 아이소바닐린을 사용하고, 아세토페논 대신 3,4-메틸렌다이옥시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 70%)을 얻었다.The title compound (yield: 70%) was obtained in the same manner as in Example 1, except that isoaniline was used instead of vanillin and 3,4-methylenedioxyacetophenone was used instead of acetophenone.

R f = 0.3 (40% 에틸아세테이트/헥산); R f = 0.3 (40% ethyl acetate / hexanes);

IR (neat, NaCl) 3340, 2969, 1671, 1460, 1265, 1176, 1055 cm-1; IR (neat, NaCl) 3340, 2969, 1671, 1460, 1265, 1176, 1055 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.73 (d, J=15.5 Hz, 1H, vinyl), 7.64 (dd, J=1.7, 1.7 Hz, 1H, Ar H), 7.52 (d, J=1.6 Hz, 1H, Ar H), 7.37 (d, J=15.5 Hz, 1H, vinyl), 7.32-7.26 (m, 1H, Ar H), 7.13 (dd, J=2.0, 2.0 Hz 1H, Ar H), 6.89 (dd, J=3.8, 6.0 Hz, 2H, Ar H), 6.05 (s, 2H, CH2), 5.69 (s, 1H, OH), 3.95 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.73 (d, J = 15.5 Hz, 1H, vinyl), 7.64 (dd, J = 1.7, 1.7 Hz, 1H, Ar H), 7.52 (d, J = 1.6 Hz , 1H, Ar H), 7.37 (d, J = 15.5 Hz, 1H, vinyl), 7.32-7.26 (m, 1H, Ar H), 7.13 (dd, J = 2.0, 2.0 Hz 1H, Ar H), 6.89 (dd, J = 3.8, 6.0 Hz, 2H, Ar H), 6.05 (s, 2H, CH 2 ), 5.69 (s, 1H, OH), 3.95 (s, 3H, OMe);

HRMS: C17H15O3에 대한 이론치 299.0919 [M+H]+, 실측치 299.0910.HRMS: calcd for C 17 H 15 O 3 299.0919 [M + H] + , found 299.0910.

실시예 8Example 8 : (: ( EE )-3-(3-하이드록시-4-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (3-hydroxy-4-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one

바닐린 대신 아이소바닐린을 사용하고, 아세토페논 대신 4-트라이플루오로메틸아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 70%)을 얻었다. The title compound (yield: 70%) was obtained in the same manner as in Example 1, except that isovanillin was used instead of vanillin and 4-trifluoromethylacetophenone was used instead of acetophenone.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3379, 2975, 1662, 1556, 1467, 1217, 1145, 1056 cm-1; IR (neat, NaCl) 3379, 2975, 1662, 1556, 1467, 1217, 1145, 1056 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 8.01 (d, J=8.3 Hz, 2H, Ar H), 7.76 (dd, J=7.5, 7.5 Hz, 3H, Ar H, vinyl), 7.34 (d, J=15.8, Hz, 1H, vinyl), 7.23 (dd, J=1.5, 1.5 Hz, 1H, Ar H ), 7.15 (d, J=1.5 Hz, 1H, Ar H), 6.97 (d, J=8.0 Hz, 1H, Ar H), 5.37 (s, 1H, OH), 3.96 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 8.01 (d, J = 8.3 Hz, 2H, Ar H), 7.76 (dd, J = 7.5, 7.5 Hz, 3H, Ar H, vinyl), 7.34 (d, J = 15.8, Hz, 1H, vinyl), 7.23 (dd, J = 1.5, 1.5 Hz, 1H, Ar H), 7.15 (d, J = 1.5 Hz, 1H, Ar H), 6.97 (d, J = 8.0 Hz , 1H, Ar H), 5.37 (s, 1H, OH), 3.96 (s, 3H, OMe);

HRMS: C17H14F3O3에 대한 이론치 323.0895 [M+H]+, 실측치 323.0880.HRMS: calc. For C 17 H 14 F 3 O 3 323.0895 [M + H] + , found 323.0880.

실시예 9Example 9 : (: ( EE )-3-(3-하이드록시-4-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (3-hydroxy-4-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one

바닐린 대신 아이소바닐린을 사용하고, 아세토페논 대신 3,4,5-트라이플루오로아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 75%)을 얻었다.The title compound (yield: 75%) was obtained in the same manner as in Example 1, except that isoaniline was used instead of vanillin and 3,4,5-trifluoroacetophenone was used instead of acetophenone.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3336, 2978, 1678, 1456, 1268, 1122, 1065 cm-1; IR (neat, NaCl) 3336, 2978, 1678, 1456, 1268, 1122, 1065 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.75 (d, J=15.5 Hz, 1H, vinyl), 7.60 (d, J=8.3 Hz, 2H, Ar H), 7.36-7.16 (m, 2H, Ar H), 7.14 (d, J=8.4 Hz, 1H, Ar H), 6.87 (d, J=8.5 Hz, 1H, vinyl), 5.75 (s, 1H, OH), 3.95 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.75 (d, J = 15.5 Hz, 1H, vinyl), 7.60 (d, J = 8.3 Hz, 2H, Ar H), 7.36-7.16 (m, 2H, Ar H ), 7.14 (d, J = 8.4 Hz, 1H, Ar H), 6.87 (d, J = 8.5 Hz, 1H, vinyl), 5.75 (s, 1H, OH), 3.95 (s, 3H, OMe);

HRMS: C16H12F3O3에 대한 이론치 309.0739 [M+H]+, 실측치 309.0751.HRMS: calcd for C 16 H 12 F 3 O 3 309.0739 [M + H] + , found 309.0751.

실시예 10Example 10 : (: ( EE )-1-(3-플루오로-4-메톡시페닐)-3-(3-하이드록시-4-메톡시페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -1- (3-fluoro-4-methoxyphenyl) -3- (3-hydroxy-4-methoxyphenyl) -1-prop-2-en-1-one

바닐린 대신 아이소바닐린을 사용하고, 아세토페논 대신 3-플루오로-4-메톡시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 80%)을 얻었다. The title compound (yield: 80%) was obtained in the same manner as in Example 1, except that isovanillin was used instead of vanillin and 3-fluoro-4-methoxyacetophenone was used instead of acetophenone.

R f = 0.3 (25% 에틸아세테이트/헥산); R f = 0.3 (25% ethyl acetate / hexanes);

IR (neat, NaCl) 3355, 2976, 1682, 1458, 1276, 1120, 1076 cm-1; IR (neat, NaCl) 3355, 2976, 1682, 1458, 1276, 1120, 1076 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.95-7.78 (m, 2H, Ar H), 7.76 (d, J=15.5 Hz, 1H, vinyl), 7.39-7.27 (m, 2H, Ar H), 7.15-7.04 (m, 2H, Ar H), 6.84 (d, J=4.8 Hz, 1H, vinyl), 5.77 (s, 1H, OH), 3.97 (s, 3H, OMe), 3.94 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.95-7.78 (m, 2H, Ar H), 7.76 (d, J = 15.5 Hz, 1H, vinyl), 7.39-7.27 (m, 2H, Ar H), 7.15 -7.04 (m, 2H, Ar H), 6.84 (d, J = 4.8 Hz, 1H, vinyl), 5.77 (s, 1H, OH), 3.97 (s, 3H, OMe), 3.94 (s, 3H, OMe );

HRMS: C17H16FO4에 대한 이론치 303.1033 [M+H]+, 실측치 303.1045.HRMS: calc. For C 17 H 16 FO 4 303.1033 [M + H] + , found 303.1045.

실시예 11Example 11 : (: ( EE )-3-(2-하이드록시-3-메톡시페닐)-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (2-hydroxy-3-methoxyphenyl) -1-phenylprop-2-en-1-one

바닐린 대신 오쏘바닐린을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 89%)을 얻었다. The title compound (yield: 89%) was obtained by the same method as Example 1, except that orthovanillin was used instead of vanillin.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3340, 2987, 1670, 1448, 1285, 1122, 1084 cm-1; IR (neat, NaCl) 3340, 2987, 1670, 1448, 1285, 1122, 1084 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 8.12 (d, J=15.8 Hz, 1H, vinyl), 8.00 (d, J=6.9 Hz, 2H, Ar H), 7.73 (d, J=15.8 Hz, 1H, vinyl), 7.65-7.42 (m, 3H, Ar H), 7.23 (d, J=7.8 Hz, 1H, Ar H), 6.90 (d, J=8.5 Hz, 1H, Ar H), 6.79 (d, J=7.8 Hz, 1H, Ar H), 4.66 (s, 1H, OH), 3.84 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 8.12 (d, J = 15.8 Hz, 1H, vinyl), 8.00 (d, J = 6.9 Hz, 2H, Ar H), 7.73 (d, J = 15.8 Hz, 1H , vinyl), 7.65-7.42 (m, 3H, Ar H), 7.23 (d, J = 7.8 Hz, 1H, Ar H), 6.90 (d, J = 8.5 Hz, 1H, Ar H), 6.79 (d, J = 7.8 Hz, 1H, Ar H), 4.66 (s, 1H, OH), 3.84 (s, 3H, OMe);

HRMS: C16H15O3에 대한 이론치 255.1021 [M+H]+, 실측치 255.1012.HRMS: calcd for C 16 H 15 O 3 255.1021 [M + H] + , found 255.1012.

실시예 12Example 12 : (: ( EE )-3-(2-하이드록시-3-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (2-hydroxy-3-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one

바닐린 대신 오쏘바닐린을 사용하고, 아세토페논 대신 3,4-메틸렌다이옥시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 68%)을 얻었다. The title compound (yield: 68%) was obtained in the same manner as in Example 1, except that orthovanillin was used instead of vanillin and 3,4-methylenedioxyacetophenone was used instead of acetophenone.

R f = 0.3 (40% 에틸아세테이트/헥산); R f = 0.3 (40% ethyl acetate / hexanes);

IR (neat, NaCl) 3345, 2977, 1675, 1465, 1248, 1166, 1045 cm-1; IR (neat, NaCl) 3345, 2977, 1675, 1465, 1248, 1166, 1045 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.73 (d, J=15.6 Hz, 1H, vinyl), 7.65 (d, J=7.8 Hz, 1H, Ar H), 7.61 (d, J=4.8 Hz, 1H, Ar H), 7.31 (d, J=15.6 Hz, 1H, vinyl), 7.22 (d, J=3.2 Hz, 1H, Ar H), 6.92 (dd, J=4.8, 1.6 Hz, 1H, Ar H), 6.88-6.79 (m, 2H, Ar H), 6.05 (s, 2H, CH2), 5.78 (s, 1H, OH), 3.88 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.73 (d, J = 15.6 Hz, 1H, vinyl), 7.65 (d, J = 7.8 Hz, 1H, Ar H), 7.61 (d, J = 4.8 Hz, 1H , Ar H), 7.31 (d, J = 15.6 Hz, 1H, vinyl), 7.22 (d, J = 3.2 Hz, 1H, Ar H), 6.92 (dd, J = 4.8, 1.6 Hz, 1H, Ar H) , 6.88-6.79 (m, 2H, Ar H), 6.05 (s, 2H, CH 2 ), 5.78 (s, 1H, OH), 3.88 (s, 3H, OMe);

HRMS: C17H15O3에 대한 이론치 299.0919 [M+H]+, 실측치 299.0936.HRMS: calcd for C 17 H 15 O 3 299.0919 [M + H] + , found 299.0936.

실시예 13Example 13 : (: ( EE )-3-(2-하이드록시-3-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (2-hydroxy-3-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one

바닐린 대신 오쏘바닐린을 사용하고, 아세토페논 대신 4-트라이플루오로메틸아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 75%)을 얻었다.The title compound (yield: 75%) was obtained in the same manner as in Example 1, except that orthovanillin was used instead of vanillin and 4-trifluoromethylacetophenone was used instead of acetophenone.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3350, 2979, 1675, 1458, 1244, 1065 cm-1; IR (neat, NaCl) 3350, 2979, 1675, 1458, 1244, 1065 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.98 (d, J=8.0 Hz, 2H, Ar H), 7.55 (d, J=15.8 Hz, 1H, vinyl), 7.51 (d, J=7.5 Hz, 2H, Ar H), 7.34 (d, J=15.8, Hz, 1H, vinyl), 7.22 (dd, J=2.5, 2.5 Hz, 1H, Ar H), 7.11 (d, J=3.5 Hz, 1H, Ar H), 6.94 (d, J=8.0 Hz, 1H, Ar H), 5.45 (s, 1H, OH), 3.93 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.98 (d, J = 8.0 Hz, 2H, Ar H), 7.55 (d, J = 15.8 Hz, 1H, vinyl), 7.51 (d, J = 7.5 Hz, 2H , Ar H), 7.34 (d, J = 15.8, Hz, 1H, vinyl), 7.22 (dd, J = 2.5, 2.5 Hz, 1H, Ar H), 7.11 (d, J = 3.5 Hz, 1H, Ar H ), 6.94 (d, J = 8.0 Hz, 1H, Ar H), 5.45 (s, 1H, OH), 3.93 (s, 3H, OMe);

HRMS: C17H14F3O3에 대한 이론치 323.0895 [M+H]+, 실측치 323.0872.HRMS: calc. For C 17 H 14 F 3 O 3 323.0895 [M + H] + , found 323.0872.

실시예 14Example 14 : (: ( EE )-3-(2-하이드록시-3-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (2-hydroxy-3-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one

바닐린 대신 오쏘바닐린을 사용하고, 아세토페논 대신 3,4,5-트라이플루오로아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 77%)을 얻었다. The title compound (yield: 77%) was obtained in the same manner as in Example 1, except that orthovanillin was used instead of vanillin and 3,4,5-trifluoroacetophenone was used instead of acetophenone.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3405, 2987, 1675, 1540, 1455, 1247, 1130, 1060 cm-1; IR (neat, NaCl) 3405, 2987, 1675, 1540, 1455, 1247, 1130, 1060 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.99 (d, J=15.5 Hz, 1H, vinyl), 7.76 (d, J=7.5 Hz, 2H, Ar H), 7.34 (d, J=15.5, Hz, 1H, vinyl), 7.23 (dd, J=3.5, 3.5 Hz, 1H, Ar H), 7.18 (d, J=6.5 Hz, 1H, Ar H), 6.93 (d, J=7.5 Hz, 1H, Ar H), 5.54 (s, 1H, OH), 3.91 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.99 (d, J = 15.5 Hz, 1H, vinyl), 7.76 (d, J = 7.5 Hz, 2H, Ar H), 7.34 (d, J = 15.5, Hz, 1H, vinyl), 7.23 (dd, J = 3.5, 3.5 Hz, 1H, Ar H), 7.18 (d, J = 6.5 Hz, 1H, Ar H), 6.93 (d, J = 7.5 Hz, 1H, Ar H ), 5.54 (s, 1H, OH), 3.91 (s, 3H, OMe);

HRMS: C16H12F3O3에 대한 이론치 309.0739 [M+H]+, 실측치 309.0722.HRMS: calcd for C 16 H 12 F 3 O 3 309.0739 [M + H] + , found 309.0722.

실시예 15Example 15 : (: ( EE )-1-(3-플루오로-4-메톡시페닐)-3-(2-하이드록시-3-메톡시페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -1- (3-fluoro-4-methoxyphenyl) -3- (2-hydroxy-3-methoxyphenyl) -1-prop-2-en-1-one

바닐린 대신 오쏘바닐린을 사용하고, 아세토페논 대신 3-플루오로-4-메톡시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 81%)을 얻었다. The title compound (yield: 81%) was obtained in the same manner as in Example 1, except that orovanillin was used instead of vanillin and 3-fluoro-4-methoxyacetophenone was used instead of acetophenone.

R f = 0.3 (25% 에틸아세테이트/헥산); R f = 0.3 (25% ethyl acetate / hexanes);

IR (neat, NaCl) 3352, 2979, 1687, 1466, 1285, 1122, 1084 cm-1; IR (neat, NaCl) 3352, 2979, 1687, 1466, 1285, 1122, 1084 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 8.20 (d, J=15.5 Hz, 1H, vinyl), 8.11-8.06 (m, 2H, Ar H), 7.96 (d, J=15.5 Hz, 1H, vinyl), 7.41 (dd, J=3.5, 3.5 Hz, 1H, Ar H), 7.22 (t, J=8.4 Hz, 1H, Ar H), 7.16-7.03 (m, 2H, Ar H), 6.56 (s, 1H, OH), 4.21 (s, 3H, OMe), 4.17 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 8.20 (d, J = 15.5 Hz, 1H, vinyl), 8.11-8.06 (m, 2H, Ar H), 7.96 (d, J = 15.5 Hz, 1H, vinyl) , 7.41 (dd, J = 3.5, 3.5 Hz, 1H, Ar H), 7.22 (t, J = 8.4 Hz, 1H, Ar H), 7.16-7.03 (m, 2H, Ar H), 6.56 (s, 1H , OH), 4.21 (s, 3H, OMe), 4.17 (s, 3H, OMe);

HRMS: C17H16FO4에 대한 이론치 303.1033 [M+H]+, 실측치 303.1053.HRMS: calc. For C 17 H 16 FO 4 303.1033 [M + H] + , found 303.1053.

실시예 16Example 16 : (: ( EE )-3-(3,4-다이메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온의 합성Synthesis of) -3- (3,4-dimethoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one

바닐린 대신 3,4-다이메톡시벤즈알데하이드를 사용하고, 아세토페논 대신 3,4-메틸렌다이옥시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 73%)을 얻었다. The title compound (yield: 73%) was obtained in the same manner as in Example 1, except that 3,4-dimethoxybenzaldehyde was used instead of vanillin and 3,4-methylenedioxyacetophenone was used instead of acetophenone. Got it.

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3305, 2965, 1681, 1455, 1240, 1033 cm-1; IR (neat, NaCl) 3305, 2965, 1681, 1455, 1240, 1033 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.73 (d, J=15.5 Hz, 1H, vinyl), 7.63 (dd, J=1.7, 1.7 Hz, 1H, Ar H), 7.52 (d, J=1.6 Hz, 1H, Ar H), 7.30 (d, J=15.5 Hz, 1H, vinyl), 7.21 (d, J=2.5, 2.5 Hz, 1H, Ar H), 7.15 (d, J=1.8 Hz, 1H, Ar H), 6.89 (d, J=7.5 Hz, 2H, Ar H), 6.05 (s, 2H, CH2), 3.95 (s, 3H, OMe), 3.93 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.73 (d, J = 15.5 Hz, 1H, vinyl), 7.63 (dd, J = 1.7, 1.7 Hz, 1H, Ar H), 7.52 (d, J = 1.6 Hz , 1H, Ar H), 7.30 (d, J = 15.5 Hz, 1H, vinyl), 7.21 (d, J = 2.5, 2.5 Hz, 1H, Ar H), 7.15 (d, J = 1.8 Hz, 1H, Ar H), 6.89 (d, J = 7.5 Hz, 2H, Ar H), 6.05 (s, 2H, CH 2 ), 3.95 (s, 3H, OMe), 3.93 (s, 3H, OMe);

HRMS: C18H17O5에 대한 이론치 313.1076 [M+H]+, 실측치 313.1092.HRMS: calc. For C 18 H 17 O 5 313.1076 [M + H] + , found 313.1092.

실시예 17Example 17 : (: ( EE )-3-(3,4-다이메톡시페닐)-1-(3-플루오로-4-메톡시페닐)-1-프로프-2-엔-1-온의 합성Synthesis of) -3- (3,4-dimethoxyphenyl) -1- (3-fluoro-4-methoxyphenyl) -1-prop-2-en-1-one

바닐린 대신 3,4-다이메톡시벤즈알데하이드를 사용하고, 아세토페논 대신 3-플루오로-4-메톡시아세토페논을 사용한 것을 제외하고는 상기 실시예 1과 동일한 방법으로 표제 화합물 (수율: 89%)을 얻었다. The title compound (yield: 89% in the same manner as in Example 1) except that 3,4-dimethoxybenzaldehyde was used instead of vanillin and 3-fluoro-4-methoxyacetophenone was used instead of acetophenone. )

R f = 0.3 (30% 에틸아세테이트/헥산); R f = 0.3 (30% ethyl acetate / hexanes);

IR (neat, NaCl) 3030, 2988, 1697, 1512, 1264, 1120, 1064 cm-1; IR (neat, NaCl) 3030, 2988, 1697, 1512, 1264, 1120, 1064 cm −1 ;

1H NMR (500 MHz, CDCl3) δ 7.68 (d, J=15.6 Hz, 1H, vinyl), 7.65-7.41 (m, 2H, Ar H), 7.36 (d, J=15.6 Hz, 1H, vinyl), 7.21 (dd, J=2.5, 2.5 Hz, 1H, Ar H), 7.10 (d J=8.4 Hz, 1H, Ar H), 7.06-6.91 (m, 2H, Ar H), 3.91 (s, 6H, 2 × OMe), 3.83 (s, 3H, OMe); 1 H NMR (500 MHz, CDCl 3 ) δ 7.68 (d, J = 15.6 Hz, 1H, vinyl), 7.65-7.41 (m, 2H, Ar H), 7.36 (d, J = 15.6 Hz, 1H, vinyl) , 7.21 (dd, J = 2.5, 2.5 Hz, 1H, Ar H), 7.10 (d J = 8.4 Hz, 1H, Ar H), 7.06-6.91 (m, 2H, Ar H), 3.91 (s, 6H, 2 x OMe), 3.83 (s, 3H, OMe);

HRMS: C18H18FO4에 대한 이론치 317.1189 [M+H]+, 실측치 317.1196.HRMS: calc. For C 18 H 18 FO 4 317.1189 [M + H] + , found 317.1196.

Claims (8)

하기 화학식 2의 화합물과 화학식 3의 화합물을 용매 존재 하에서 리튬하이드록사이드 (LiOH)와 반응시켜 하기 화학식 1의 벤잘아세토페논 (benzalacetophenone) 유도체를 제조하는 방법: A method for preparing a benzalacetophenone derivative of Formula 1 by reacting a compound of Formula 2 with a compound of Formula 3 with lithium hydroxide (LiOH) in the presence of a solvent: <화학식 1><Formula 1>
Figure 112009044051669-pat00010
Figure 112009044051669-pat00010
 <화학식 2><Formula 2>
Figure 112009044051669-pat00011
Figure 112009044051669-pat00011
 <화학식 3><Formula 3>
Figure 112009044051669-pat00012
Figure 112009044051669-pat00012
 상기 식에서, Where X는 CH, CF, CCl, CI 또는 N이고;X is CH, CF, CCl, CI or N; Y는 C 또는 N이고; Y is C or N; R1은 수소, 하이드록시, C1-C6알킬, C1-C6알콕시, 실릴 또는 벤질이고;R 1 is hydrogen, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, silyl or benzyl; R2 및 R3는 각각 독립적으로 수소, 하이드록시, C1-C6알킬 또는 C1-C6알킬실릴이고;R 2 And each R 3 is independently hydrogen, hydroxy, C 1 -C 6 alkyl or C 1 -C 6 alkylsilyl; R4, R5 및 R6는 각각 독립적으로 수소, C1-C6알킬, 아실, 할로겐 원자, C1-C6할로알킬, C1-C6알콕시, 아미노, 나이트로 또는 산소 원자이거나, 함께 연결되어 고리화합물을 형성한다(단, X가 CH이고, Y가 C일 때, R4, R5 및 R6가 동시에 수소는 아니다).R 4 , R 5 and R 6 are each independently hydrogen, C 1 -C 6 alkyl, acyl, halogen atom, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, amino, nitro or oxygen atom, or are linked together To form a cyclic compound, provided that when X is CH and Y is C, R 4 , R 5 and R 6 are not simultaneously hydrogen; 삭제delete 삭제delete 제 1 항에 있어서, The method of claim 1, 상기 용매가 다이클로로메탄, 클로로포름, 아세토나이트릴, 다이메틸폼알데하이드, 다이메틸설폭사이드 및 이들의 혼합물, 및 메탄올, 에탄올, 부탄올, 물 및 이들의 혼합물로 이루어진 군으로부터 선택되는 것을 특징으로 하는 방법.The solvent is selected from the group consisting of dichloromethane, chloroform, acetonitrile, dimethylformaldehyde, dimethylsulfoxide and mixtures thereof, and methanol, ethanol, butanol, water and mixtures thereof. 제 4 항에 있어서, The method of claim 4, wherein 상기 용매가 메탄올인 것을 특징으로 하는 방법.The solvent is methanol. 제 1 항에 있어서,The method of claim 1, 상기 반응이 0 내지 50℃에서 1 내지 200 시간 동안 수행되는 것을 특징으로 하는 방법.The reaction is carried out at 0 to 50 ° C. for 1 to 200 hours. 제 1 항에 있어서,The method of claim 1, X가 CH이고; Y가 C이고; R1이 수소, 하이드록시 또는 C1-C6알콕시이고; R2 및 R3가 각각 독립적으로 수소 또는 C1-C6알킬이고; R4 및 R5가 각각 독립적으로 수소, C1-C6알킬, 할로겐 원자, C1-C6할로알킬, C1-C6알콕시 또는 산소 원자이거나, 함께 연결되어 고리 화합물을 형성하고; R6가 수소 또는 할로겐 원자이며, R4 및 R5가 모두 수소이면 R6가 할로겐인 것을 특징으로 하는 방법.X is CH; Y is C; R 1 is hydrogen, hydroxy or C 1 -C 6 alkoxy; R 2 And R 3 are each independently hydrogen or C 1 -C 6 alkyl; R 4 and Each R 5 is independently hydrogen, C 1 -C 6 alkyl, halogen atom, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or oxygen atom, or are linked together to form a ring compound; R 6 is hydrogen or a halogen atom, R 4 and Wherein if R 5 is all hydrogen then R 6 is halogen. 제 1 항에 있어서, The method of claim 1, 상기 화학식 1의 벤잘아세토페논 유도체가 하기 화합물로 이루어진 군으로부터 선택되는 것을 특징으로 하는 방법: Benzalacetophenone derivative of Formula 1 is characterized in that the selected from the group consisting of: 1) (E)-3-(4-하이드록시-3-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온;1) (E ) -3- (4-hydroxy-3-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one; 2) (E)-3-(4-하이드록시-3-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온;2) ( E ) -3- (4-hydroxy-3-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one; 3) (E)-3-(4-하이드록시-3-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온;3) (E ) -3- (4-hydroxy-3-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one; 4) (E)-1-(3-플루오로-4-메톡시페닐)-3-(4-하이드록시-3-메톡시페닐)-1-프로프-2-엔-1-온;4) ( E ) -1- (3-fluoro-4-methoxyphenyl) -3- (4-hydroxy-3-methoxyphenyl) -1-prop-2-en-1-one; 5) (E)-3-(3-하이드록시-4-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온;5) ( E ) -3- (3-hydroxy-4-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one; 6) (E)-3-(3-하이드록시-4-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온;6) ( E ) -3- (3-hydroxy-4-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one; 7) (E)-3-(3-하이드록시-4-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온;7) ( E ) -3- (3-hydroxy-4-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one; 8) (E)-1-(3-플루오로-4-메톡시페닐)-3-(3-하이드록시-4-메톡시페닐)-1-프로프-2-엔-1-온;8) ( E ) -1- (3-fluoro-4-methoxyphenyl) -3- (3-hydroxy-4-methoxyphenyl) -1-prop-2-en-1-one; 9) (E)-3-(2-하이드록시-3-메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온;9) ( E ) -3- (2-hydroxy-3-methoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one; 10) (E)-3-(2-하이드록시-3-메톡시페닐)-1-(4-트라이플루오로메틸페닐)-1-프로프-2-엔-1-온;10) ( E ) -3- (2-hydroxy-3-methoxyphenyl) -1- (4-trifluoromethylphenyl) -1-prop-2-en-1-one; 11) (E)-3-(2-하이드록시-3-메톡시페닐)-1-(3,4,5-트라이플루오로페닐)-1-프로프-2-엔-1-온;11) ( E ) -3- (2-hydroxy-3-methoxyphenyl) -1- (3,4,5-trifluorophenyl) -1-prop-2-en-1-one; 12) (E)-1-(3-플루오로-4-메톡시페닐)-3-(2-하이드록시-3-메톡시페닐)-1-프로프-2-엔-1-온;12) ( E ) -1- (3-fluoro-4-methoxyphenyl) -3- (2-hydroxy-3-methoxyphenyl) -1-prop-2-en-1-one; 13) (E)-3-(3,4-다이메톡시페닐)-1-[(3,4-메틸렌다이옥시페닐)]-1-페닐프로프-2-엔-1-온; 및13) ( E ) -3- (3,4-dimethoxyphenyl) -1-[(3,4-methylenedioxyphenyl)]-1-phenylprop-2-en-1-one; And 14) (E)-3-(3,4-다이메톡시페닐)-1-(3-플루오로-4-메톡시페닐)-1-프로프-2-엔-1-온.14) ( E ) -3- (3,4-dimethoxyphenyl) -1- (3-fluoro-4-methoxyphenyl) -1-prop-2-en-1-one.
KR1020070094617A 2007-09-18 2007-09-18 Method for preparing benzal acetophenone derivative KR100932071B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020070094617A KR100932071B1 (en) 2007-09-18 2007-09-18 Method for preparing benzal acetophenone derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070094617A KR100932071B1 (en) 2007-09-18 2007-09-18 Method for preparing benzal acetophenone derivative

Publications (2)

Publication Number Publication Date
KR20090029410A KR20090029410A (en) 2009-03-23
KR100932071B1 true KR100932071B1 (en) 2009-12-15

Family

ID=40696135

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070094617A KR100932071B1 (en) 2007-09-18 2007-09-18 Method for preparing benzal acetophenone derivative

Country Status (1)

Country Link
KR (1) KR100932071B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101252033B1 (en) * 2010-08-18 2013-04-15 연세대학교 산학협력단 4-Hydroxy-3-methoxyphenyl-2-propenone derivatives, preparation method thereof and antioxidant composition comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. 13, pp. 3811-3820, 2005*

Also Published As

Publication number Publication date
KR20090029410A (en) 2009-03-23

Similar Documents

Publication Publication Date Title
US5068364A (en) Chalcone derivatives and process for producing the same
CA2658652C (en) Novel process for the synthesis of (e)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol
WO2001060774A1 (en) Synthesis of resveratrol
KR100932071B1 (en) Method for preparing benzal acetophenone derivative
Bringmann et al. First total synthesis of the mastigophorenes C and D and of simplified unnatural analogs
CN103102264B (en) Preparation method of salicylic acid compound
CN101977883A (en) Process for production of 2-hydroxyaryl aldehyde compound
Cottineau et al. New synthesis of 3-methoxy-4-substituted pyrazole derivatives
JPH0616600A (en) Production of phenoxyethylamine
CN108689829B (en) Preparation method of salvianolic acid F
Shin et al. Convenient synthesis of 3-aminocoumarin derivatives by the condensation of 1, 4-diacetyl-or 3-substituent-2, 5-piperazinediones with various salicylaldehyde derivatives.
Cabiddu et al. A re-examination of the methylenation reaction
JP4759722B2 (en) Process for producing aromatic carboxylic acid ester having a substituent
Li et al. An efficient synthesis of resveratrol and a hydroxyl derivative via the Perkin reaction: cis to trans isomerisation in a demethylation process
SU1098210A1 (en) Method of producing unsaturated ketones
JPH05148175A (en) Production of p-dimethoxybenzene derivative
KR101356454B1 (en) Method of preparing unsaturated aldehyde compound
CN115724729A (en) 1-aryl-alpha, beta-unsaturated ketone compounds, synthesis method thereof and application thereof in preparation of root-knot nematode killing medicines
JPH0841005A (en) Production of 4-fluoroalkoxycynnamonitrile compound
KR101477058B1 (en) Method of preparing piridine derivatives
JP3918468B2 (en) 3,3-bis (alkoxycarbonyl-methylthio) propionitrile and process for producing the same
TWI435872B (en) 2-substituted 3-arylmethylbenzofuran
Baseer et al. IN-VITRO EVALUATION OF 2’-HYDROXY CHALCONES FOR ANTIOXIDANT ACTIVITY
KR101038394B1 (en) Synthesis of Flemichapparin A, Flemingin A, Flemingin D and their Analogues
JP2006219404A (en) Preparation method of 2-substituted-2-hydroxymethylcarboxylic ester derivative

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130226

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20131128

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20141201

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20151204

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20170605

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20171207

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee